> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panels to Discuss Pfizer NDA to Treat Severe Pain
- URL: https://www.fdaweb.com/panels-to-discuss-pfizer-nda-to-treat-severe-pain/
- Published: 2016-03-17T12:00:00.000Z
- Updated: 2026-09-15T02:44:44.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135122

*Federal Register* Notice: FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet 6/8 from 8 a.m. to 4 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committees will be asked to discuss a Pfizer NDA for oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules with the proposed indication of managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The product is an extended-release formulation intended to have abuse-deterrent properties based on the presence of naltrexone, an opioid antagonist, in the formulation. The committees will be asked to discuss whether the data submitted by the applicant are sufficient to support labeling of the product with the properties expected to deter abuse. Contact **Stephanie L. Begansky**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-03-17/pdf/2016-05999.pdf?ref=fdaweb.com)